Pathway-selective antagonism of proteinase activated receptor 2

British Journal of Pharmacology

Volumn 171, Issue 17, 2014, Pages 4112-4124

  Suen, J Y ^a   Cotterell, A ^a   Lohman, R J ^a   Lim, J ^a   Han, A ^a   Yau, M K ^a   Liu, L ^a   Cooper, M A ^a   Vesey, D A ^a   Fairlie, D P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

agonist; antagonist; biased signalling; cell signalling; GPCR; inflammation; peptide; protease; protease inhibitor; proteinase activated receptor 2

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; 5 ISOXAZOYL BETA CYCLOHEXYLALANINE ISOLEUCINE SPIROINDENE 1,4 PIPERIDINE; ACTIN; CALCIUM ION; CYCLIC AMP; FORSKOLIN; GB 88; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYOSIN LIGHT CHAIN PHOSPHATASE; PROTEIN KINASE C; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 2 BLOCKING AGENT; RECEPTOR BLOCKING AGENT; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; GB88 COMPOUND; LIGAND; OLIGOPEPTIDE;

ACTIN FILAMENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CELL TYPE; CHO CELL LINE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG SELECTIVITY; ENZYME PHOSPHORYLATION; HT 29 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CRICETULUS; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELLS, CULTURED; CHO CELLS; CRICETULUS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HT29 CELLS; HUMANS; LIGANDS; OLIGOPEPTIDES; RATS; RECEPTOR, PAR-2; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84906069480     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12757     Document Type: Article

References (53)

1. Abbenante G, Fairlie DP, (2005). Protease inhibitors in the clinic. Med Chem 1: 71-104.
2. Adams MN, Ramachandran R, Yau MK, Suen JY, Fairlie DP, Hollenberg MD, et-al. (2011). Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther 130: 248-282.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et-al. (2013a). The concise guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et-al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels. Br J Pharmacol 170: 1607-1651.
5. Amadesi S, Grant AD, Cottrell GS, Vaksman N, Poole DP, Rozengurt E, et-al. (2009). Protein kinase D isoforms are expressed in rat and mouse primary sensory neurons and are activated by agonists of protease-activated receptor 2. J Comp Neurol 516: 141-156.
6. Badeanlou L, Furlan-Freguia C, Yang G, Ruf W, Samad F, (2011). Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation. Nat Med 17: 1490-1497.
7. Barry GD, Le GT, Fairlie DP, (2006). Agonists and antagonists of protease activated receptors (PARs). Curr Med Chem 13: 243-265.
8. Barry GD, Suen JY, Le GT, Cotterell A, Reid RC, Fairlie DP, (2010). Novel agonists and antagonists for human protease activated receptor 2. J Med Chem 53: 7428-7440.
9. Blakeney JS, Reid RC, Le GT, Fairlie DP, (2007). Nonpeptidic ligands for peptide-activated G protein-coupled receptors. Chem Rev 107: 2960-3041.
10. Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, et-al. (2007). Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 117: 636-647.
11. Chen Y, Yang C, Wang ZJ, (2011). Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. Neuroscience 193: 440-451.
12. Cocks TM, Fong B, Chow JM, Anderson GP, Frauman AG, Goldie RG, et-al. (1999). A protective role for protease-activated recetpors in the airways. Nature 398: 156-160.
13. Cudic M, Fields GB, (2009). Extracellular proteases as targets for drug development. Curr Protein Pept Sci 10: 297-307.
14. Di Cera E, (ed.) (2011) Proteases in Health and Disease in Progress in Nucleic Acid Research, Progress in Molecular Biology and Translational Science, Vol. 99. Academic Press: London.
15. Heutinck KM, ten Berge IJ, Hack CE, Hamann J, Rowshani AT, (2010). Serine proteases of the human immune system in health and disease. Mol Immunol 47: 1943-1955.
16. Hirota CL, Moreau F, Iablokov V, Dicay M, Renaux B, Hollenberg MD, et-al. (2012). Epidermal growth factor receptor transactivation is required for proteinase-activated receptor-2-induced COX-2 expression in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 303: G111-G119.
17. Hoffman J, Flynn AN, Tillu DV, Zhang Z, Patek R, Price TJ, et-al. (2012). Lanthanide labeling of a potent protease activated receptor-2 agonist for time-resolved fluorescence analysis. Bioconjug Chem 23: 2098-2104.
18. Hollenberg MD, Mihara K, Polley D, Suen JY, Han A, Fairlie DP, et-al. (2014). Biased signaling and proteinase-activated receptors (PARs): targeting inflammatory disease. Review. Br J Pharmacol 171: 1180-1194.
19. Huang ZJ, Li HC, Cowan AA, Liu S, Zhang YK, Song XJ, (2012). Chronic compression or acute dissociation of dorsal root ganglion induces cAMP-dependent neuronal hyperexcitability through activation of PAR2. Pain 153: 1426-1437.
20. Kawabata A, Matsunami M, Tsutsumi M, Ishiki T, Fukushima O, Sekiguchi F, et-al. (2006). Suppression of pancreatitis-related allodynia/hyperalgesia by proteinase-activated receptor-2 in mice. Br J Pharmacol 148: 54-60.
21. Kenakin T, (2011). Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336: 296-302.
22. Kenakin TP, (2012). Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br J Pharmacol 165: 1659-1669.
23. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
24. Klabunde T, Hessler G, (2002). Drug design strategies for targeting G-protein-coupled receptors. Chembiochem 3: 928-944.
25. Kobilka B, Schertler GF, (2008). New G-protein-coupled receptor crystal structures: insights and limitations. Trends Pharmacol Sci 29: 79-83.
26. Kobilka BK, (2011). Structural insights into adrenergic receptor function and pharmacology. Trends Pharmacol Sci 32: 213-218.
27. Kobilka BK, Deupi X, (2007). Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 28: 397-406.
28. Leung D, Abbenante G, Fairlie DP, (2000). Protease inhibitors: current status and future prospects. J Med Chem 43: 305-341.
29. Lim J, Iyer A, Liu L, Suen JY, Lohman RJ, Seow V, et-al. (2013). Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism. FASEB J 27: 4757-4767.
30. Lohman RJ, Cotterell AJ, Barry GD, Liu L, Suen JY, Vesey DA, et-al. (2012a). An antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats. FASEB J 26: 2877-2887.
31. Lohman RJ, Cotterell AJ, Suen J, Liu L, Do AT, Vesey DA, et-al. (2012b). Antagonism of protease-activated receptor 2 protects against experimental colitis. J Pharmacol Exp Ther 340: 256-265.
32. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
33. Moore CS, Crocker SJ, (2012). An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol 180: 12-16.
34. Moussa L, Apostolopoulos J, Davenport P, Tchonque J, Tipping PG, (2007). Protease-activated receptor-2 augments experimental crescentic glomerulonephritis. Am J Pathol 171: 800-808.
35. Nichols HL, Saffeddine M, Theriot BS, Hegde A, Polley D, El-Mays T, et-al. (2012). beta-Arrestin-2 mediates the proinflammatory effects of proteinase-activated receptor-2 in the airway. Proc Natl Acad Sci U S A 109: 16660-16665.
36. Nishimura A, Kitano K, Takasaki J, Taniguchi M, Mizuno N, Tago K, et-al. (2010). Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule. Proc Natl Acad Sci U S A 107: 13666-13671.
37. Pejler G, Ronnberg E, Waern I, Wernersson S, (2010). Mast cell proteases: multifaceted regulators of inflammatory disease. Blood 115: 4981-4990.
38. Qi W, Johnson DW, Vesey DA, Pollock CA, Chen X, (2007). Isolation, propagation and characterization of primary tubule cell culture from human kidney. Nephrology (Carlton) 12: 155-159.
39. Quirk K, Roberts DJ, Strange PG, (2007). Mechanisms of G protein activation via the D2 dopamine receptor: evidence for persistent receptor/G protein interaction after agonist stimulation. Br J Pharmacol 151: 144-152.
40. Rajagopal S, Rajagopal K, Lefkowitz RJ, (2010). Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9: 373-386.
41. Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD, (2012). Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov 11: 69-86.
42. Reibman J, Talbot AT, Hsu Y, Ou G, Jover J, Nilsen D, et-al. (2000). Regulation of expression of granulocyte-macrophage colony-stimulating factor in human bronchial epithelial cells: roles of protein kinase C and mitogen-activated protein kinases. J Immunol 165: 1618-1625.
43. Sharony R, Yu PJ, Park J, Galloway AC, Mignatti P, Pintucci G, (2010). Protein targets of inflammatory serine proteases and cardiovascular disease. J Inflamm 7: 45.
44. Shukla AK, Violin JD, Whalen EJ, Gesty-Palmer D, Shenoy SK, Lefkowitz R, (2008). Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. Proc Natl Acad Sci U S A 105: 9988-9993.
45. Suen JY, Gardiner B, Grimmond S, Fairlie DP, (2010). Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cells. PLoS ONE 5: e13809.
46. Suen JY, Barry GD, Lohman RJ, Halili MA, Cotterell AJ, Le GT, et-al. (2012). Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). Br J Pharmacol 165: 1413-1423.
47. Turk B, (2006). Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5: 785-799.
48. Tyndall JDA, Pfeiffer B, Abbenante G, Fairlie DP, (2005). Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. Chem Rev 105: 793-826.
49. Vergnolle N, Chignard M, (eds) (2011) Proteases and Their Receptors in Inflammation, Progress in Inflammation Research. Springer: Basel AG.
50. Vesey DA, Cheung CW, Kruger WA, Poronnik P, Gobe G, Johnson DW, (2005). Thrombin stimulates proinflammatory and proliferative responses in primary cultures of human proximal tubule cells. Kidney Int 67: 1315-1329.
51. Vesey DA, Kruger WA, Poronnik P, Gobe GC, Johnson DW, (2007). Proinflammatory and proliferative responses of human proximal tubule cells to PAR-2 activation. Am J Physiol Renal Physiol 293: F1441-F1449.
52. Vesey DA, Qi W, Chen X, Pollock CA, Johnson DW, (2009). Isolation and primary culture of human proximal tubule cells. Methods Mol Biol 466: 19-24.
53. Yau MK, Liu L, Fairlie DP, (2013). Toward drugs for protease-activated receptor 2 (PAR2). J Med Chem 56: 7477-7497.